Summary A randomized phase 11 trial was performed to compare the efficacy and toxicity of interleukin 2 (IL-2) with an IL-2 and interferon alpha (IFN-a) regimen for the treatment of metastatic renal carcinoma. Sixty patients with recurrent renal cell carcinoma (RCC) who had previously undergone a nephrectomy were randomized to receive three cycles of IL-2 or IL-2 with IFN-a,. Eighteen al. 1996).
The treatment of metastatic renal carcinoma (RCC) is frustrating,. Chemotherapy is largely ineffecti-e and standard therapy revolves around the administration of cvtokines such as interleukin 2 (LL-2) and interferon alpha (dFN-c). Typically. these agents are associated with an objectixe response rate of 15-207c. although higher doses of IL-2 have been reported to induce a 30%7c response rate (Canobbio et al. 1996a : Goev et al. 1996 : Savage et al. 1996 . Response rates and sun-ix-al are strongly influenced by patient selection so that those who have a good performance status. a single site of metastatic disease and a prolonged disease-free interxal follow-ing initial surgery fare better (Palmer et al. 1992 : Fossa et al. 1995 : Canobbio et al. 1996a : Goey et al. 1996 : Savage et al. 1996 .
Experimental data suggested that a combination of IL-2 and IFN-a might offer superior efficacy. Interferon enhances the cell membrane expression of major histocompatibility complex (MHC) antigens to %%-hich IL-2-activated T cells can respond (Guadagni et al. 1989) . A sxnergistic response was confirmed in mice (Cameron et al. 1988 ) and this led to the development of combination regimens that were associated wvith an ox erall response rate of up to 29%7 (Atzpodien et al. 1990 . 1991 : Palmer et al. 1993 : Canobbio et al. 1996b : Gause et al. 1996 : Savage et al. 1996 wxith a median survival of 8-12 months (Facendola et al. 1995 : Canobbio et al. 1996a . Nexertheless. the toxicity of combination cytokine therapy includes fatiglue.
hN-potension and creatinine elexvation (Atkins et al. 1993 : Gause et al. 1996 . factors that led to the premature discontinuation of therapy in 14% of patients (Facendola et al. 1995) .
We haxe performed a phase I trial to determine the maximum Evaluation of toxicity Toxicity was evaluated according to National Cancer Institute common toxicity criteria (NCI-CTC). (Figure 1 ). In addition. there was a trend to suggest that those patients who were treated with IL-2 alone had a longer time to progression after therapy. although this was not statistically sianificant ( Figure 2 ).
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Patient characteristics
Toxicity of treatment
The toxicity of the cytokines resulted in 26 and 22 patients receiving two and three cycles of IL-2 therapy. whereas only 25 and 14 patients received 2 and 3 cycles of IL-2IFN-ax, treatment respectively. The principal toxicities of the therapy are recorded in (Palmer et al. 1992 : Canobbio et al. 1996b : Fossa et al. 1995 : Goey et al. 1996 : Savage et al. 1996 . In series that have investigated patients with two or more sites of disease, the response rates can be as low as 8% (Canobbio et al. 1995) . On the other hand. the objective response rate is higher in studies in which most patients have one site of metastatic disease (Atzpodien et al. 1995 : Tourani et al. 1996 .
The median survival intervals of the patients in the two arms were similar and compare favourably with the results of other assessments of IL-2 (Walpole et al. 1993 : Tourani et al, 1996 . Those who were treated with IL-2 alone survived for a median of The increased toxicity of this cytokine combination suggests either that further evaluation of the IL-2/IFN-aL, combination should be confined to large prospective randomized trials or that the less toxic but more active 5-fluorouracil /IL-2/IFN-a,, combinations (Atzpodien et al, 1993) should be fiunher explored.
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